Nancy Lurker - Feb 9, 2023 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
CEO, Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Feb 9, 2023
Transactions value $
$0
Form type
4
Date filed
2/13/2023, 03:56 PM
Previous filing
Jan 10, 2023
Next filing
May 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +17.5K +11.46% $0.00 171K Feb 9, 2023 Direct F1
transaction EYPT Common Stock Options Exercise $0 +20K +11.73% $0.00 191K Feb 9, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -20K -33.33% $0.00 40K Feb 9, 2023 Common Stock 20K $0.00 Direct F2
transaction EYPT Restricted Stock Units Options Exercise $0 -17.5K -50% $0.00 17.5K Feb 9, 2023 Common Stock 17.5K $0.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 2,745 shares acquired on January 31, 2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 The restricted stock units vest in three annual installments beginning February 9, 2023.
F3 The restricted stock units vest in three ratable annual installments beginning February 9, 2022.